In this section, we explore the power of the 10% pullback strategy—an approach that helps investors buy stocks at lower prices during market pullbacks. Learn how to spot these opportunities, manage risk, and make smarter, more informed decisions when stocks temporarily correct. Perfect for traders looking to buy quality stocks on sale and boost long-term returns.
Investing in PPB Group Berhad (PPB) for the long term can be appealing for several reasons, but it's important to take into account both the company's strengths and potential risks. Here's a detailed look at why someone might consider long-term investment in PPB Group Bhd.
MISC Bhd (Malaysian International Shipping Corporation) is a prominent player in the maritime industry, and its stock could be appealing for long-term investors due to several factors.
Investing in Texas Instruments for the long term could be a solid choice due to its market leadership in analog and embedded processing, consistent financial performance, and strong growth prospects in high-demand sectors like automotive, industrial automation, and IoT.
Procter & Gamble Co. combination of solid financials, dependable cash flow, dividend payments, and market-leading brands make it a strong candidate for long-term investment. The company’s defensive nature and ability to weather economic storms, alongside its commitment to innovation and sustainability, give investors confidence in its long-term growth potential.
Investing in Sime Darby Berhad (SIME Darby) for the long term can be appealing for several reasons, given its diversified business portfolio, solid market position, and growth potential. Below are some key aspects that may support a long-term investment thesis for Sime Darby.
Investing in Berkshire Hathaway for the long term offers a blend of stability, growth, and reliable management. It provides exposure to a diverse portfolio of businesses, each benefiting from strong economic moats and backed by a disciplined, long-term investment approach.
AbbVie has shown consistent revenue growth, supported by a robust pipeline of treatments and a strong market presence. While the company’s blockbuster drug Humira (adalimumab) has been a cash cow for many years, its revenue generation power remains substantial, even as biosimilars begin to challenge its dominance.
Investing in IHH Healthcare Berhad (IHH) can be appealing for several reasons, especially if you're looking at long-term growth and stability. IHH is a major player in the healthcare industry, particularly in Asia, and its stock can offer good potential.